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ABSTRACT
Streptococcus pneumoniae is a major cause of morbidity and mortality in children and 
adults worldwide. The spectrum of infections caused by Streptococcus pneumoniae is 
well-characterized. The bacteria is transmitted via droplets/aerosols to the nasal cavity, 
from which it is spread locally to ears, sinuses, bronchi, lungs, blood (septicemia) and CNS 
(meningitis). In the perspective of increasing global antibiotic resistance and the reported 
shift of pneumococcal types post vaccination, alternative preventive actions might be 
warranted in the future. In order to prevent or cure pneumococcal infection, it is therefore 
important to investigate the adhesion capacity of the bacterium to cells/receptors and also to 
investigate the response of the immune system to Streptococcus pneumoniae. 
To investigate Streptococcus pneumoniae binding to human cell receptors, an ELISA was 
developed where the binding to two previously proposed receptors could be compared 
in the same test system. The results showed that Streptococcus pneumoniae adhered to 
the human cell receptor glycolipid asilao-GM1, in which the specific binding site was 
characterized as the disaccharide GalNAcβ1-4Gal. In response to the results showing 
asialo-GM1 as a human cell receptor for Streptococcus pneumoniae, further investigation 
aimed to determine the pneumococcal structure that would adhere to this receptor. One of 
the pneumococcal surface structures is the cell wall polysaccharide, CWPS, which contains 
phosphoryl choline. 
To investigate whether CWPS was the pneumococcal ligand binding to asialo-GM1, 
carbohydrate material was extracted from an uncapsulated strain of pneumococci. 
The carbohydrate material in the extract was separated and fractions binding to the 
pneumococcal glycolipid receptor asialo-GM1 were detected. In nuclear magnetic 
resonance spectroscopy (NMR) analysis, these fractions exhibited a pattern consistent with 
a reference spectrum of pure CWPS. The purified CWPS adhered to asialo-GM1 without 
protein involvement as it was unaffected by CWPS exposure to proteinase K.
Streptococcus pneumoniae grown under conditions where choline was replaced with 
ethanolamine did not bind to the host cell receptor asialo-GM1. This indicated that CWPS, 
with intact phosphoryl choline residues, is the ligand responsible for binding pneumococci 
to the glycolipid receptor asialo-GM1.
Having determined CWPS as the responsible ligand to host cell receptor asialo-GM1, 
the immune response toward this structure deserved more detailed analyses. This was 
investigated in regard to CWPS activation of a subset of immune cells. Apart from CWPS, 
Streptococcus pneumoniae also expose other important polysaccharides surrounding 
the bacterium, i.e. the capsule. The composition of the capsule differs between different 
Streptococcus pneumoniae bacteria and hence classifies these into different types. 
Different sets of capsules are used in commercial available pneumococcal vaccines. The 
present study examined CWPS as well as some capsular polysaccharides included in the 
pneumococcal vaccines, for their individual capacity to activate immune cells. 
CWPS, three different capsular polysaccharides (types 3, 9 and 23) and LPS (positive 
control) were used for in vitro stimulation of whole blood. CWPS and the three capsules 
activated the immune cells differently (measured as CD69 expression). Generally, NK cells 
and NK-like T cells exhibited the strongest activation followed by monocytes and T cells.
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Among the three capsules, capsule type 23 induced the strongest activation and cytokine 
release, followed by type 9 and type 3. In these experiments, CWPS induction was well in 
the range of what was seen from type 23.
CWPS is also a Toll Like Receptor (TLR) 2 ligand, and was investigated together with 
other TLR2 and TLR4 ligands for their capacity to induce gene expression and cytokine 
release from isolated monocytes and NK cells. Incubation of isolated peripheral blood 
monocytes with CWPS induced transcriptional upregulation and subsequent secretion of 
several major proinflammatory cytokines and chemokines, similar to the other TLR ligands 
investigated. CWPS as well as the other TLR ligands exhibited significant upregulation of 
CXCL8 expression in isolated NK cells.
With the results showing that CWPS is the ligand responsible for binding pneumococci 
to the host cell glycolipid receptor asialo-GM1 and also having confirmed that CWPS 
is an effective activator of immune cells, its impact in clinical settings (smokers) was 
investigated.
Cigarette smoking is a well-known and high risk factor for infections of Streptococcus 
pneumoniae. The study investigated whether the TLR ligands (including CWPS) would 
induce a different immune response in smokers compared to non-smokers. In these 
experiments no difference in TLR gene expression could be detected between smokers and 
non-smokers in unstimulated cells. 
Following CWPS incubation with isolated monocytes, cells from smokers showed an 
increased upregulation of pro-inflammatory mediators as compared to non-smokers. 
Monocytes from non-smokers downregulated  the immune regulatory molecules IL-10 
and SOCS-1 after CWPS stimulation, while this was not found in smokers. The results 
suggest that the transcriptional activation of pro-inflammatory genes after TLR activation is 
dysregulated in smokers.
Marianne Sundberg Kövamees
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SAMMANFATTNING
Infektioner orsakade av pneumokocker är en vanlig orsak till sjuklighet och dödlighet 
runt om i världen. Enligt WHO inträffade ca 14,5 miljoner episoder av allvarlig 
pneumokocksjukdom år 2000. Bakterien sprids som droppsmitta från friska bärare, som är 
koloniserade med bakterien i näshålan, samt från personer sjuka i pneumokocksjukdom. 
Från näshålan sprids pneumokockbakterien vidare till olika delar av kroppens 
lokalisationer. Vanligast är spridning till öron, bihålor och lungor men bakterien kan också 
spridas vidare till blod och hjärnhinnor.
På grund av resistensutveckling mot antibiotika hos bakterier samt det faktum att 
tillgängliga vacciner inte skyddar mot alla sjukdomsframkallande pneumokocker, är det 
viktigt att undersöka bakteriens bindning och kolonisation på humana celler. Genom att 
studera dessa mekanismer samt deras påverkan på immunförsvarets reaktioner för att 
eliminera pneumokocker ökas kunskapen om hur man i framtiden kan bekämpa denna 
bakterie.
För att närmare undersöka pneumokockers bindning till mänskliga celler var målet i arbete 
I att utveckla ett testsystem för att påvisa pneumokockers bindning till två föreslagna 
bindningsmolekyler, s.k. receptorer, och därefter jämföra påvisad bindningskapacitet 
hos pneumokocker till respektive receptor. Ett test utvecklades där de två föreslagna 
pneumokockreceptorerna (asialo-GM1 och lactotriaocylceramid), samtidigt kunde 
analyseras i ett och samma testsystem, vilket inte varit möjligt tidigare. Resultaten visade 
att pneumokocker band till båda receptorerna men att bindningen till en av dem (asialo-
GM1 receptorn) var starkare. Testet möjliggjorde även fördjupad utredning av vilken 
struktur på pneumokocken som band till asialo-GM1 receptorn. 
I arbete II var syftet att utreda med vilken struktur pneumokockerna band till receptorn, 
asialo-GM1. Pneumokocker odlades och separerades i två olika faser, en proteinfas och 
en sackaridfas. I sackaridfasen separerades de olika ingående sackariderna från varandra 
och testades därefter för bindningskapacitet till asialo-GM1 i det tidigare nämnda testet. 
Genom detta förfarande isolerades den specifika sackarid som band till asialo-GM1 
receptorn. Materialet analyserades därefter med nuclear magnetic resonance spectroscopy 
(NMR), en metod som undersöker egenskaperna hos organiska molekyler, vilken visade 
att det framrenade ämnet överensstämde med en cellväggs polysackarid (CWPS), som 
pneumokocker exponerar på sin yta. Sackariden är gemensam för alla pneumokocktyper. 
För att närmare undersöka vilken struktur i CWPS som band till receptorn, odlades 
bakterierna i olika definierade odlingsmedium, innehållande antingen cholin eller 
etanolamin som infogas i CWPS under bakterietillväxt. Pneumokocker som odlats i cholin-
innehållande medium band fortfarande till receptorn, till skillnad mot de etanolaminodlade 
pneumokockerna som inte band. Cholin behövs alltså för att kunna binda till receptorn, och 
förmodas vara den struktur med vilken pneumokocker binder till asialo-GM1. 
I arbete III var syftet att närmare undersöka immunsvaret mot CWPS samt mot tre 
olika kapselsackarider. Pneumokocker förekommer i 97 stycken så kallade kapseltyper. 
Vilka av dessa kapseltyper som orsakar sjukdom varierar över tid, geografisk region, 
ålder och övriga sjukdomar hos individen. Kapslarna från sjukdomsframkallande 
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pneumokocker ingår i pneumokockvaccin. Det ena tillgängliga vaccinet består av 23 olika 
kapselpolysackarider och det andra vaccinet består av 7, 10 eller 13 olika kapselsackarider 
kopplade till ett protein (konjugerat vaccin). Vaccin som består av endast kapselsackarider 
ger ett rent B-cellssvar, dvs produktion av skyddande antikroppar. Det proteininnehållande, 
konjugerade vaccinet, ger förutom ett B-cellsvar även ett T-cellsvar, som förstärker 
B-cellssvaret samt genererar T-minnesceller. 
I arbete III undersöktes aktiveringen av olika immunceller genom deras utsöndring av 
cytokiner (små proteiner som påverkar andra celler) efter exponering av CWPS och tre 
olika pneumokockkapslar, samtliga ingående i pneumokockvaccinet. Stimuleringen och 
mätningarna gjordes i blod från friska individer. 
Både CWPS och kapslarna aktiverade immuncellerna, men i olika grad. Den högsta 
aktiveringsgraden uppvisade NK-celler och NK-liknande T-celler, följt av monocyter. 
CWPS aktiverade i regel cellerna i högre grad än vad kapslarna gjorde, undantaget 
monocyter. Kapslarna skiljde sig åt från varandra avseende förmåga att aktivera 
immunsvaret. Kapseltyp 23 aktiverade immuncellerna starkast, därefter följde kapseltyp 
9 och lägst aktiveringsgrad uppvisade kapseltyp 3. Den uppmätta cytokinfrisättningen 
följde samma mönster som cellaktiveringen för kapslarna. Studien hjälper till att öka 
förståelsen för effektvariationer för pneumokockvaccin-komponenter och kan därför bidra 
till utveckling av förbättrade vacciner mot pneumokocker.
På flera celltyper i immunförvaret, såsom makrofager, dendritiska celler, neutrofiler, 
T- och B-celler finns Toll-lika receptorer (TLR) som bland annat känner igen CWPS hos 
pneumokocker. Bindningen till TLR initierar en kaskad av intracellulära signaler som 
resulterar i produktion av proinflammatoriska cytokiner. I arbete IV undersöktes genuttryck 
och även sekretion av proinflammatoriska mediatorer i isolerade monocyter och NK-celler, 
efter stimulering med substanser som aktiverar TLR (såsom CWPS, Pam3CSK4 och LPS). 
Studien visade att CWPS från S. pneumoniae ökar genuttryck för inflammatoriska 
mediatorer i isolerade humana monocyter och i isolerade NK-celler. Det uppmätta 
genuttrycket för de inflammatoriska mediatorerna var mer uttalat i monocyter från rökare. I 
monocyter från icke rökare uppmättes en nedreglering av immunreglerande molekyler, efter 
CWPS stimulering, vilket inte var fallet hos rökare. Denna studie visar också att cigarettrök 
påverkar immunförsvaret hos friska rökare med normal lungfunktion.
Marianne Sundberg Kövamees
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CBA Cytometric bead array
CbpA Choline binding protein A
CD Cluster if differentiation
CDC Centers for Disease Control and prevention
COPD Chronic Obstructive Pulmonary lung disease
CRP C reactive protein
CWPS Cell Wall Polysaccharide
DAMP Danger associated molecular patterns
DNA Deoxyribonucleic acid
ELISA Enzyme linked immunosorbent assay
FACS Fluorescence activated cell sorter
FEV1 Forced Expiratory Volume during one second
FITC Fluorescein isothiocyanate
FSC Forward scatter (cell size)
IPD Invasive pulmonary disease
Ig Immunoglobulin
IL Interleukin
LPS Lipopolysaccharide
LR Laminin Receptor
LTA Lipoteichoic acid
mAB Mono clonal antibody
MFI Median, or mean fluorescence intensity
MHC Major histocompability complex
NET Neutrophil extracellular traps 
NK-cell Natural killer cell
NKT Natural killer T cell 
NOD Nucleotide- binding oligomerization domain
NLR NOD like receptors
NMR Nuclear magnetic resonance
OD Optical Density
PBMC Peripheral blood mononuclear cells
PCho Phorohoryl choline
PCR Polymerase Chain Reaction
PCV Pneumococcal conjugate vaccine
PG Peptidoglycan
PPV Pneumococcal polysaccharide vaccine
PRR Pattern recognition receptors
PAF Platelet activating factor
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PAMP Pathogen associated molecular patterns
PIgR Polymeric immunoglobulin receptor
PsrP Pneumococcal serine-rich repeat protein
RIG Retinoc acid-inducer
RLR RIG-like-1 receptor
RNA Ribonukleinsyra
SOCS Suppressor of cytokine signaling
SSC Side scatter (cell granularity)
STAT Signal transducer and activator of transcription
TA Teichoic acid
Th cell T helper cell 
TNF Tumor necrosis factor 
TLR Toll like receptor
WHO World Health Organisation      
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History
One-hundred and thirty-six years ago, in the year of 1881, Streptococcus pneumoniae was 
first isolated and described separately by two scientists, Pasteur in France and Sternberg in 
the United States. Pasteur isolated pneumococci and described what today is known as the 
capsule (1) while Sternberg described a micrococcus, 0,5µm in diameter, joined in pairs in 
the blood of infected rabbits (1). Soon afterwards, Friedländer, Fraenkel and Weichselbaum 
described the association of pneumococcus with pneumococcal disease (1). Seven years 
later Klemperers demonstrated a protective effect of antiserum against pneumococcal dis-
ease.
In the beginning of year 1900, Neufeld described the technique for typing of the pneu-
mococcal capsule, which was named “the quelling reaction”. This method is still used to 
distinguish between the different capsular types of pneumococci. However, the method was 
not used for identification of human pneumococcal capsules until 1931(1). In the 1920´s, 
Avery and Morgan concluded that the specific soluble substance of S. pneumococcus is a 
polysaccharide (1). Exploring that finding in 1945, a tetravalent vaccine composed of four 
different pneumococcal capsular polysaccharides was used in experiments for human im-
munization and subsequently prevented type-specific pneumococcal pneumonia (2).
In 1928, seventeen years before this proven protective effect of immunization against pneu-
mococcal disease, penicillin was discovered by Alexander Fleming. Penicillin has been of 
the greatest importance for the treatment of pneumococcal disease. Together with Florey 
and Chain, Fleming was awarded the Nobel Prize in 1945, for “the discovery of penicillin 
and its curative effect in various infectious diseases” (3). From having been a true “wonder-
drug”, penicillin lately has been somewhat hampered by the increasing resistance in pneu-
mococci and other bacteria.
In the same year as the discovery of penicillin, the discovery of the natural transformation 
capacity in pneumococci was made by Griffith. In these experiments, mice were injected 
subcutaneously with a virulent capsulated pneumococcal strain type 3 that was heat killed, 
together with a living, non-virulent uncapsulated pneumococcal strain type 2. The combina-
tion of the two strains resulted in a virulent type 3 strain. This indicated that virulence could 
be transformed between the bacterial strains (4). Eventually, in 1944 Avery discovered that 
the transforming material responsible for the results in Griffths experiment was indeed 
nucleic acid (5).
Epidemiology
Infection due to Streptococcus pneumoniae is a well-known major cause of morbidity and 
mortality worldwide. In 2015, it was estimated that 1.5 million people worldwide died from 
pneumococcal pneumonia (6). Pneumococci are thought to be transmitted via droplets/
aerosols, mostly from persons already colonized in the nasopharynx, healthy carriers, or 
by direct contact with patients suffering from pneumococcal disease (Figure 1). Among the 
healthy carriers, children are the most frequently infected with a peak incidence at the age 
of 2-3 years. Thereafter the colonization in the nasopharynx is reduced to < 10% in adults 
INTRODUCTION AND BACKGROUND
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without children/close contact with children (7). Initially the bacteria enter the nasal cavity, 
where colonization in the nasopharyngeal epithelium takes place. From the primary infec-
tion site, the bacteria can then spread locally to bronchi, lungs, ears or sinuses. In addition, 
if bacteria cross the mucosal barrier, they enter the bloodstream resulting in bacteremia. 
Once established in the bloodstream, distal infections may occur and upon passage of the 
blood-brain barrier, the bacteria may cause meningitis (7). The specific pneumococcal sero-
types, described below, differ between geographical region, age, disease syndrome/severity 
and also over time (8). In general, young children and elderly, as well as immunocompro-
mised patients, have a high risk for being infected. However, also individuals with a recent 
history of influenza virus infections and patients with comorbidities, such as chronic lung 
disease, heart disease, malignancies and diabetes have a higher incidence of pneumococcal 
disease (9). 
Microbiology
As indicated by its name and mentioned above, Streptococcus pneumoniae is a main agent 
for pneumonia, predominately of the lobar type. Streptococcus pneumoniae is a gram posi-
tive coccus. The bacteria most often grow in pairs, as the diplococci described by Stern-
berg in 1881, but may also occur in short chains or even as single cells. The individual 
size of the cells are between 0,5 µm and 1,25 µm in diameter. The bacteria are capable of 
growing in oxygen-rich as well as in oxygen-poor environments. Pneumococci are con-
veniently identified by alpha-hemolysis on blood-agar plates, or by optochin sensitivity. 
During alpha-hemolysis, the pneumococcal enzyme pneumolysin degrades hemoglobin in 
Figure 1. Progression of pneumococcal disease from the nasopharynx to sinuses, ears, lungs, blood stream 
and to the central nervous system (CNS). Modified from U. R. Goonetilleke et al., 2009, Interdisciplinary 
Perspectives on Infectious Diseases (108).
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the blood-agar, converting it into a green pigment, which can be easily spotted around the 
bacterial colonies. Optochin (ethylhydrocupreine hydrochloride) on the other hand, inhibits 
the growth of pneumococci in vitro and hence is used in the diagnostics of Streptococcus 
pneumoniae infection. Pneumococci also lack the enzyme catalase and are soluble in bile 
salts and by deoxycholate (10), exposing other possible ways to identify this specific agent. 
The bacteria are surrounded by a polysaccharide capsule. Each pneumococcal strain can be 
identified and typed by the swelling of the capsule upon its binding to homologous antibod-
ies, the Quellung reaction (swelling reaction) (10). In cases of non-typeable pneumococcai, 
an additional possibility of identification is molecular diagnostics, which include detection 
of certain pneumococcal specific genes, such as autolysin (10). 
Capsule
The pneumococcal cell surface is covered with capsular polysaccharides. Until today 97 
different capsular serotypes have been described, exhibiting variations in their sugar com-
position and linkage (11, 12). The capsule is considered to be the major virulence factor of 
the Streptococcus pneumoniae. Clinical isolates causing invasive disease are all capsulated, 
loss of capsule will dramatically reduce virulence (8, 14). The capsule exerts important 
functions such as acting as a steric hindrance and preventing phagocytosis (7, 13). In a 
mouse model, Avery et al. demonstrated the importance of capsular virulence when this was 
reduced, after enzymatic digestion of the serotype 3 capsule (14). The virulence differs be-
tween pneumococcal strains depending on the capsular serotype (15, 16). The pneumococ-
cal vaccines are based on different capsular pneumococcal polysaccharides. 
Pneumococcal colonies can spontaneously undergo a phase variation from an opaque state, 
suitable for survival in blood, to become transparent, adapted for colonization in the naso-
pharynx (17). The increased virulence of opaque pneumococci is associated with increased 
expression of capsular polysaccharide and decreased expression of teichoic acids compared 
with the transparent phenotype (18). Serospecific antibodies are protective against respec-
tive capsule (19). In the pneumococcal chromosome, the genes coding for the biosynthesis 
and expression of capsules are closely linked (20).
Cell Wall
The cell wall of Streptococcus pneumoniae consists of an outer layer built up by  peptido-
glycan, teichoic acid and lipoteichoic acid (21) surrounding an inner layer consisting of a 
double phospholipid membrane. The peptidoglycan (PG) is associated with both teichoic 
acid (TA) and lipoteichoic acid (LTA). LTA and TA are chemically identical compounds, but 
differs in their attachment to the cell wall (21, 22) (Figure 2). LTA is anchored by its lipo 
part located into the cytoplasmic membrane, while TA is covalently bound to PG. Both TA 
and LTA contain phosphorylcholine (PCho), which is the binding site for choline binding 
proteins (23). PCho also adheres to platelet-activating factor receptor (PAFr) on host cells 
(24) and is also recognized by C-reactive protein (CRP), a protein in the immune system, 
capable of activating complement (25). CRP originally received its name due to the reactiv-
ity with pneumococcal teichoic acid, or C-polysaccharide, as pneumococcal teichoic acid 
was previously named (26). Cell wall polysaccharide (CWPS) is also known as a teichoic 
acid. Based on genomic analyzes, the surface proteins in the pneumococcal cell wall can be 
divided into one of three different groups; choline binding proteins, that are non-covalently 
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linked to the cell wall, lipoproteins anchored in the cell wall peptidoglycan and proteins 
with a LP X TG motif covalently bound and anchored in the cell wall (21). Purified cell 
wall components and  whole pneumococci result in the same inflammatory response (27). 
Cell walls induce inflammation by white blood cell activation and cytokine release (28).
Immune response
The human body has different ways of defending itself against microbes, these include 
physical barriers such as skin and mucous as well as protection of airways by the cough 
mechanism and sneeze reflexes which perform a mechanical clearance of the mucus, pro-
duced by epithelial cells in the respiratory tract. Microbes caught in this secretion are also 
transported away by cilia. 
If the microbe succeeds to penetrate the physical barrier, it encounters the immune cells and 
molecules that are always present in tissues. The innate immune defense is comparatively 
unspecific, while the adaptive immune defense is highly specific and effective. Although 
more efficient, it is also slower, since T- and B-cells must undergo clonal expansion and dif-
ferentiation after activation by the current microbe. The adaptive defense has a long-lasting 
memory, thereby often protecting from reinfections caused by the same microbe.
In the bone marrow, hematopoietic stem cell develops into either lymphoid stem cells 
which mature into lymphocytes or into myeloid stem cells, which in turn develop further 
Figure 2. This stylized representation of the pneumococcal cell wall shows the 12 identified choline 
binding proteins (Cbps) bound via a conserved binding domain to the choline component of teichoic 
acid or lipoteichoic acid (blue circles on dark blue structures) which are in turn anchored to either 
peptidoglycan (green) or the plasma membrane. Modified from Jonathan A. McCullers et al., 2001, 
Frontiers in Bioscience (109).
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into monocytes, granulocytes, mast cells, red blood cells and platelets. Monocytes may 
further develop into macrophages and dendritic cells. The various white blood cells, mono-
cytes, macrophages, lymphocytes and granulocytes as well as mast cells and dendritic cells 
together build up the cellular part of our immune system.
Cell types in the innate immune system
Monocytes, macrophages, dendritic cells
Monocytes develop in bone marrow and afterwards migrate into the blood and further into 
different tissues where they differentiate into macrophages or dendritic cells. These cells 
have antigen presenting molecules on their surfaces, the major histocompatibility complex 
(MHC) molecules. Most cell types in the human body express MHC class I, while MHC 
class II molecules are present on antigen presenting cells such as the previously described 
macrophages and dendritic cells. Macrophages and dendritic cells are found in all tissues 
of the human body. After phagocytosis of foreign substances by macrophages and dendritic 
cells, they are transported to lymphoid organs, where peptides derived from the foreign sub-
stances (antigens) are presented to T-helper cells. Monocytes, macrophages, and dendritic 
cells are all important producers of cytokines and initiates phagocytosis.
Granulocytes
Granulocytes are divided into three different subgroups. These are; neutrophilic, eosino-
philic and basophilic granulocytes. In the blood, the neutrophilic granulocytes are the most 
common. These granulocytes have a phagocytic function and are short lived. They have 
the capacity to release cytokines and to start inflammation. Granulocytes are stored in large 
quantities in the bone marrow and may rapidly be released to the blood when needed in 
response to various stimuli.
NK cells
NK-cells also develop in the bone marrow. They have both activating and inhibitory recep-
tors and capacity to secrete various cytokines. The NK-cell receptors can identify infected 
or abnormal cells and enable the NK-cells to quickly kill them by secretion of cytotoxic 
substances. They also have the ability to secrete cytokines that stimulate both the innate and 
the adaptive defense system via dendritic cells and Th1 cells.
Complement system
The complement system consists of more than 30 circulating or cell-bound proteins pro-
duced in the liver. When in contact with microbes these proteins trigger a cascade of reac-
tions which help to defend the body (29). The main functions of the complement system are 
opsonization to promote phagocytosis and activation of neutrophil chemotaxis, eventually 
killing the microbe. Complement activation is a multistage process where the most impor-
tant step is the cleavage of factor C3 into C3a and C3b. C3b can then opsonize and facilitate 
phagocytosis. The complement system may be activated by three different mechanisms. The 
classical complement activation pathway occurs by the recognition of an antigen-antibody 
complex or the complex between the antigen and non-antibody acute phase protein, for 
example CRP. The alternative activation pathway initiates the degradation of C3 to C3b, on 
the cell surface of microbes. Finally, the lectin activation pathway is initiated when lectin 
recognize carbohydrates bound to mannose on the microbe (29).
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Cytokines and Chemokines
Cytokines are small proteins, mostly glycoproteins, with highly specific activity. They are 
produced by different cells in the immune system. They act as communicators between the 
immune cells by secretion and then binding to receptors on the immune cell membrane. 
This binding then initiates intracellular signals, which may have both activating and in-
hibitory effects. As a result, a certain cytokine may have several different effects and also 
different cytokines may exert the same effect. Cytokines are involved in the innate as well 
as the adaptive immune system. Pro-inflammatory cytokines are secreted by macrophages, 
dendritic cells, mast cells and granulocytes. Adaptive defense cytokines are secreted by 
lymphocytes, especially T-helper cells. Cytokines can affect the own cell (autocrine), the 
closest cells (paracrine) or cells far away from the producing cell (endocrine).
Chemokines are a distinct group of small signal proteins affecting migration of cells. They 
stimulate leukocyte movement and direction of migration.
Pattern Recognition Receptors, PRR
The cells in the innate immune system have receptors called pattern recognition receptor 
(PRR). They recognize specific molecules called pathogen associated molecule patterns, 
PAMPs, on microorganisms. Cells from humans or other mammals do not have these mole-
cule patterns. There are three different groups of PRR; membrane-bound Toll-like receptors 
(TLRs), intracellular retinoic acid-inducer (RIG)-1-like receptors (RLRs), and nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs).
TLRs are the most studied PRRs. LPS, found in gram-negative bacterial cell wall, is the 
most studied PAMP. C-reactive protein (CRP) is an example of PRR in soluble form.
Toll-like receptors
TLRs recognize PAMPs from bacteria, parasites, fungi and viruses. The binding initiates a 
cascade of intracellular signaling, which results in production of proinflammatory cytokines 
and interferons. The intracellular signaling cascade is negatively regulated. One of the main 
regulators is suppressor of cytokine signaling-1, SOCS-1. In humans there are 10 known 
TLRs found on several cell types, such as macrophages, dendritic cells, neutrophils, T and 
B cells but also on epithelial cells and fibroblasts. TLR2 recognizes pneumococcal lipo-
teichoic acid (LTA) (29), bacterial lipopeptides, yeast ligands, parasitic and viral proteins 
(30). TLR4 is known as the LPS receptor but it also recognizes pneumolysin, a cytotoxin 
of pneumococci, as well as host heat shock proteins, fibrinogen and certain viral proteins. 
Pneumococcal DNA, like other bacterial DNA of the so-called CpG type, is recognized by 
TLR9.
NOD like receptors
NOD like receptors (NLRs) are a family consisting of more than 20 cytoplasmic receptors 
that are activated by both intracellular and extracellular pathogens. NLRs initiate signaling 
that promotes an immunological response (31). mRNA upregulation of NOD1 and NOD2 
expression is seen after pneumococcal infection in mouse lung tissue and bronchial epithe-
lial cell line (32). NOD2, in turn, recognizes peptidoglycan fragments from pneumococcai 
digested by lysosome in mice (33).
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Cells in the adaptive immunity
The cells responsible for the adaptive immune system are B-lymphocytes and T-lympho-
cytes. Antigens are identified by B-cell membrane-bound antibodies and T-cell receptors. 
Each lymphocyte recognizes only one specific antigen. The B-cell membrane-bound anti-
bodies (B-cell receptors) recognize parts of proteins, lipids, carbohydrates, nucleic acids 
and chemical groups. The T-cell receptors (TCRs) recognize peptides presented by MHC 
class I or class II molecules on antigen-presenting cells.
The adaptive immune response is activated and develops when it is exposed to antigen and 
the immunity created depends on the agents for which it is exposed. Although slower, the 
adaptive immunity is more specific and more powerful when exposed to the same antigen, 
compared to the innate immunity. The adaptive immunity also generates a valuable memory 
for antigen elimination. Antigens can be divided into eliciting T-cells dependent response, 
or T-cells independent response. Capsule polysaccharides generate an independent response 
(34). MHC II on antigen presenting cells are incapable to present polysaccharides, and 
hence no specific T-cell depending response is elicited. Antigens causing an independent 
response cannot conduct isotype switch for production of B cells with specific affinity and 
memory.
Lymphocytes
There are three different groups of lymphocytes; T cells, Natural Killer cells (NK cells) and 
B cells. The T cells develop in the bone marrow and then migrate to thymus where full ma-
turity and function are reached. Here, most autoreactive T cells (i.e. reactive to substances 
in the body) are eliminated. Each T cell has a T cell receptor that recognizes only one spe-
cific antigen. In the body there are (before specific antigen encounter) only a few T cells 
bearing any particular, specific T cell receptor but the total population of T cells contains an 
enormous diversity of T cell receptors. In order for the T cell to differentiate and proliferate 
(undergo clonal expansion), the antigen needs to be presented together with an antigen pre-
senting molecule, MHC. T cells are divided into subspecialized groups such as cytotoxic T 
cells / killer cells (CD8pos), T helper cells (CD4pos) and Regulatory T cells, T-reg cells.
T helper (Th) cells have the CD4pos receptor on their surface and bind to MHC class II on 
antigen presenting cells. Upon binding, they release cytokines and chemokines that activate 
and recruit other immune cells, such as macrophages, B lymphocytes, cytotoxic T lympho-
cytes (CD8pos). The mature Th cells can be divided into different subclasses, Th1, Th2 and 
Th17. They have different cytokine profiles, thus affecting the immune system in different 
ways (35). The cytotoxic T cells (Tc) express the CD8pos receptor on their surface. The T 
Cell Receptor (TCR) of CD8pos cells bind to MHC class I on host cells infected with mi-
crobes. Upon binding, Tc secrete lytic proteins, after which the host cells are lysed. There 
are also regulatory T cells, T-reg cells, which are capable of inhibiting some immune re-
sponses.
B cells
The B cell is predetermined to produce one type of antibody for a specific antigen. Upon 
activation, the B cells increase in number, all with the same type of antibody production 
capacity. Some of the cells produce antibodies while others become memory cells for later 
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use. Antibodies are proteins that prevent the antigen from binding to its target cell by block-
ing or neutralization. B cells may also function as an antigen presenting cell to activate Th 
cells by presenting antigens on MHC class II. Some antigens composed of large molecules 
of repetitive carbohydrates, such as polysaccharide capsules from pneumococci, can acti-
vate T cell-independent B cells in the spleen, providing a rapid antibody response to such 
bloodborne pathogens.
Antibodies
There are several antibody isotypes; IgM, IgA, IgG, IgE and IgD. The different isotypes 
have different functions, eg neutralization, opsonization or complement binding. The B 
cells first express IgM and IgD but may after further activation switch to produce IgG, IgA 
or IgE with the exact same antigen specificity. Upon repeated exposure to the same agent, 
IgG (or IgA, IgE) response arise much faster and with early high affinity due to the memory 
B-cells. Most B-memory cells produce IgG antibodies. IgM consists of five antibodies 
linked together. IgM and IgG both have a binding site for complement factor C1. IgG exists 
in the largest amount of all antibodies and is able to pass over the placenta. In humans there 
are four IgG subclasses, IgG1-4. IgG1 and IgG3 activate complement and constitute anti-
bodies to protein antigens, and IgG2 against polysaccharide antigens. Decreased amount of 
IgG2 subclass may provide poorer defense against encapsulated bacteria such as pneumo-
cocci. IgA is present in monomeric form in the serum and on various mucous membranes 
as secretory IgA and can be transferred to breast milk. IgA blocks the binding of bacteria, 
viruses and toxins in the mucous membranes. IgE is found in mast cells and connected to 
allergic and anaphylactic reactions. IgD predominantly exists in membrane-bound form but 
may be present in small amounts in serum. Its function is still unclear.
Pneumococcal immunity
The classical host defense mechanism against pneumococci is phagocytosis of bacteria op-
sonized by complement or antibodies. The classical pathway is the most important portion 
of the complement system in the response to pneumococci. The C-reactive protein, CRP, a 
soluble PRR, also activates complement by binding to the cell wall polysaccharide, CWPS 
(36). Several TLRs of host cells recognize pneumococcal PAMPs, and initiate an immuno-
logic response. TLRs recognize different parts of pneumococci, e.g. TLR2 recognizes bac-
terial LTA, TLR 4 recognizes pneumolysin and TLR9 recognize pneumococcal DNA (29).
B-cells are important in the defense against pneumococci in producing anti-capsular anti-
bodies. Antibodies against CWPS are thought to mediate protection against invasive disease 
(37, 38). Certain IL-17 producing T cells are protective against extracellular bacteria such 
as Streptococcus pneumoniae (39). The anti-pneumococcal defense involves a variety of 
cytokines, IL-6, IL-12, IL-17, IL-18, and TNF and IL-1 (29). NLRs are intracellular PRR of 
the host cell and one of the NRLs, NOD2, recognizes small fragments from pneumococcal 
peptidoglycan (31). 
Pneumococci can escape the immune system in several ways. The capsule acts as steric hin-
drance and prevents phagocytosis. The capsule also prevents binding of both IgG and CRP 
to S. pneumoniae and thereby inhibits the classical complement activation pathway (13). 
Surface proteins that help to avoid the immune system are PspA, which reduce complement 
binding to the pneumococcus (40) and CpbA that counteracts complement (41). Pneumo-
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cocci can also cause repulsion of neutrophil extracellular traps (NETs) by a positive charge 
on the surface of the bacterium due to the composition of LTA (42). 
Prevention
Pneumococcal vaccines
Already back in 1914, initial experiments were performed regarding a pneumococcal 
vaccine containing whole killed bacteria (43). In 1945 MacLeod showed that type specific 
infections in humans could be prevented with a type-specific 4-valent pneumococcal 
polysaccharide vaccine (2). However, it was not until the 1970s that pneumococcal 
polysaccharide vaccine was licensed. In 1983 a vaccine containing 23 pneumococcal 
capsular polysaccharides (PPV 23) was introduced containing the most frequently occurring 
serotypes of invasive pneumococcal disease (IPD). The vaccine has also been shown to 
contain CWPS (44). The elicited immunological response to vaccination depends on the 
age of the patient and varies between different serotypes. PPV is a T cells independent 
antigen that generates B cells that activate and provide the antibody response. PPV elicits 
a weak immune response in children under the age of 2 years. Since 2000, there is also a 
conjugated pneumococcal vaccine (PCV) where the capsular saccharides are linked to a 
carrier protein, diphtheria carrier protein CRM. PCV contains T cell-dependent antigens 
that provides both B-cell activation and antibodies and a T-cell response, including T-cell 
memory. The first PCV was protective against 7 pneumococcal serotypes (4, 6B, 9V, 14, 
18C, 19F, 23F). Since 2015, PCV7 has been replaced by PCV10 (PCV7 + 1, 3, 7F) or 
PCV13 (PCV10 + 19A, 6A, 3). Compared to PPV, PCV is more immunogenic and provides 
more effective protection against infection, even for children under 2 years of age. PCV 
effectively reduces the frequency of invasive pneumoccocal disease for the serotypes 
included in the vaccine (9, 45). The vaccine protects both against systemic and mucosal 
infection and prevents colonization in the nasopharynx. This also prevents dissemination 
in society. Between 2007 and 2009, the conjugated vaccine (PCV) was introduced in the 
Swedish childhood vaccination program. After vaccination with PCV reports have shown a 
change in carriage and IPD of pneumoccocal serotypes to types not included in the vaccine. 
This was observed in both the vaccinated and the non-vaccinated population (9).
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• To develop an ELISA adhesion test, in order to investigate suggested host cell 
receptor molecules for their specific binding to S pneumoniae, and to compare the 
adhesive ability of the various receptors.
• To identify and characterize the pneumococcal ligand responsible for binding to 
host cell asialo-GM1, using a non-capsular pneumococcal strain.
• To investigate cell wall polysaccharide (CWPS) and individual capsular 
polysaccharides from S pneumoniae for their ability to activate immune cell subsets 
from healthy controls and to quantify cytokine levels after stimulation.
• To investigate gene expression and secretion of inflammatory mediators in isolated 
monocytes and NK cells from healthy individuals after stimulation with three 
different TLR ligands, including CWPS, and comparing smokers with non-smokers.
OBJECTIVE AND AIMS
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Bacterial strains and culture conditions (Articles I and II)
The different pneumococcal strains used in Article 1 and 2 were CCSR-SCS-2 clone 1 
(type 12) (46) (Article I), R36A (type 2 mutant without capsule) (Articles I and II), CCUG 
6605 (type 19) (Article I) and CCUG 2987 (type 23) (Article I). The bacteria in Article 
I were grown on blood agar plates at 37º C overnight, and then diluted in buffer (TRIS 
buffered saline or anti hydrophobic PSM buffer) to OD 1.0 at 600 nm. In Article II, R36A 
grown on blood agar plates was inoculated into liquid brain heart infusion BHI, with 5% 
fetal calf serum or into a defined medium (47). The defined medium was further divided 
into two different variants where one contained phosphorylcholine, while the other version 
of the defined medium contained ethanolamine instead of phosphorylcholine. In order to 
secure that ethanolamine had been properly incorporated, the bacteria were cultured in this 
phosphorylcholine-free medium for four rounds. Prior to the experiments, all bacteria were 
cultured to OD 0.8 at 600 nm. After growth in liquid medium, the bacteria were washed in 
PBS and diluted in the test buffer.
Enzyme-linked immunosorbent assay, ELISA (Articles I and II).
Microtiter plates were coated with the receptors, asialo-GM1 (Articles I and II) and lacto-
triaocylceramide (Article I) in concentrations ranging from 1 ng/ml to 10 µg/ml (Article 
I) and 10 µg/ml (Article II) in 100 µl methanol. The methanol was evaporated at 37º C for 
18 h at room temperature (RT). The plates were then coated with 1% BSA in TBE for 1 h 
in RT. The bacteria, diluted in 1% BSA in TBE or in antihydrophobic PSM buffer, were 
then added to the microtiter plates in 1:2 dilutions spanning from OD 1.0 to 0.003 (Article 
I), and to OD 0.8 (Article II) at 600nm. In Article II, bacteria, purified saccharide and heat 
extracted soluble bacterial substances were also tested for binding to the receptor asialo-
GM1. The saccharide material and bacteria were diluted in antihydrophobic solution. The 
heat extract was diluted in TBS. Bacteria, saccharide material and heat extract were added 
to coated wells (described above) and incubated for 1 h at 37º C. As negative controls, wells 
without receptor (Articles I and II) and wells coated with E. coli LPS (Article I) were used.
Detection of bound bacteria (Articles I and II), saccharide material (Article II) and heat 
extract (Article II) was performed either using a monoclonal mouse anti-phosphorylcholine 
antibody and subsequently a rabbit anti-mouse antibody or a polyclonal rabbit anti-pneu-
mococcal serum (46). In both cases an alkaline phosphate conjugated swine anti-rabbit 
antibody was used. Analyses were done in spectrophotometer at 405 nm, after addition of 
phosphate substrate for 30 minutes.
Preparation of cell wall polysaccharide (Article II)
In the preparation of cell wall polysaccharide (CWPS), the bacteria were cultured to OD 
1.0 at 600 nm in BHI supplemented with the addition of 5% FCS and 1% glucose. Bacteria 
were then washed in 0.9% NaCl before hot phenol-water extraction, which separates the 
saccharides and the proteins. The aqueous phase was dialyzed against running tap water 
to remove any phenol residues before freeze-drying. The saccharides were purified by gel 
permeation chromatography. The lyophilized material was dissolved in distilled water con-
taining 1% butanol and run on a 100 ml Sephadex G-100 column with 0.5 ml saccharide 
METHODS
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(10 mg / ml). From the column, 2.5 ml fractions were collected and every second fraction 
was tested in Elisa for binding to asialo-GM1. The procedure was repeated 16 times. The 
material from the fractions that bound to asialo-GM1 with an absorption > 0.2 at 405 nm, 
were pooled and freeze dried.
Extraction of soluble substances from whole bacteria (Article II)
To investigate the immunological properties of soluble substance from whole bacteria, bac-
teria were grown in medium to OD 1.0, at 600 nm. After washing in PBS, the bacteria were 
diluted to OD 1.0 at 600 nm and incubated in water bath at 65° C for 40 minutes. Follow-
ing centrifugation, the supernatant was stored in 1/10 of concentrated polyethylene glycol 
20 000.
Dot blot (Article II)
The purified CWPS preparation (described above) was examined using Dot blot. After 
saccharides were applied to the nitrocellulose filters, the filters were blocked with TRIS 
buffered saline containing 0.05% Tween-20, in TTBS for 1h. Then, after initial incubation 
with a monoclonal antibody to the repeating part of the C-polysaccharide (46), sequential 
incubations with a rabbit anti-mouse antibody and by an HPR-conjugated goat anti-rabbit 
antibody followed. The filters were then developed with the substrate (4-chloro-1-naphtol) 
and the reaction was stopped by applying tap water. Between each of the described steps 
the filters were washed in TTBS.
Treatment	of	purified	saccharide	with	protease	and	dissociating	agents	(Article	II)
To eliminate proteins from the purified saccharide preparation and also from the heat 
extract, 0.5 mg/ml saccharide and heat extract were treated with protease K (50 µg/ml) 
for 1 hour at 20° C. The reaction was stopped by boiling for 4 minutes. The material was 
dialyzed in PBS at 4° C overnight. The protease K treated and dialyzed material was exam-
ined in ELISA for binding to asialo-GM1 as well as on SDS-page and in Western blot. The 
lyophilized saccharide material (0.5 mg/ml) was also treated with either 1M urea for 30 
minutes or exposed to 6M guanidine-HCl for 15 minutes at 20° C. The material was finally 
dialyzed in PBS at 4° C.
SDS gel electrophoresis and Western blot (Article II)
Bacteria, heat extract and purified pneumococcal saccharide material were also investigated 
in 12% SDS gel, for 45 minutes (100V, 54mA). The separated material in the gel was then 
transferred to nitrocellulose paper at 100V, 250mA for 30 minutes after which the filter was 
blocked for 2 hours in TTBS. To detect the material on the nitrocellulose paper, a rabbit 
anti-pneumococcal antibody or a mouse anti-phosphoryl choline monoclonal antibody was 
applied for 1 hour. For detection of the mouse monoclonal antibody, an additional antibody, 
a rabbit anti-mouse IgG, was used. Finally, the nitrocellulose filters were incubated with an 
HRP conjugated goat anti-rabbit IgG. For development, substrate 4-chloro-1-naphtol was 
added and the reaction was eventually stopped with tap water.
Subjects and blood samples (Article III and IV)
In Article III, healthy adults, non-pneumococcal vaccinated subjects aged 42 to 59 were 
enrolled. Venous blood was obtained in heparinized test tubes. 500 µl of whole blood was 
added to 12-well microtiter plates.
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In Article IV (manuscript), 21 healthy non-smokers and smokers were recruited. Non-
smokers had smoked less than 100 cigarettes in total and not smoked at all for the last 12 
months. The smokers that were included had all a smoking consumption equal to or more 
than 5 “pack years”, ie. the number of smoked cigarettes per day/20 x number of years. 
In Article IV, all subjects were examined by dynamic spirometry. At the time of sampling 
no subject had airway infection or allergy. Every subject donated 3x8 ml of venous blood. 
PBMC (peripheral blood mononuclear cells) were isolated by Ficoll-Paque separation.
Monocytes and NK cells were then isolated by negative selection using Pan monocyte and 
NK cell isolation kit prior to an auto MACS pro separator. There was no difference in the 
amount of cells obtained from smokers and nonsmokers. Respective cell type was put into 
a 96-well microtiter plates with the volume of 200 µl/well at a concentration of 200 000 
cells/well.
Stimulation and recovery of cells (Article III and Article IV (manuscript))
In Article III, whole blood sample from test subjects was stimulated with pneumococcal 
capsular saccharides type 3, type 9 (9N) and type 23 (23F) and Streptococcus pneumoniae 
cell wall polysaccharide (CWPS) in concentration of 10 μg/ml and applying one capsule 
type per well. Incubation lasted for 4 h respective 12 h at 37 º C, in 5% CO2. As a posi-
tive control, LPS was used and as negative control, unstimulated whole blood. In Article 
IV, the isolated monocytes and the NK cells respectively initially rested for 2 hours, after 
which they were incubated with either medium or stimulated by different TLR ligands. The 
following were used in these experiments: TLR4 ligand; lipopolysaccharide from E coli 
K12 (LPS), 100 ng/ml, TLR 2 ligand: Streptococcus pneumoniae cell wall polysaccharide 
(CWPS), 10μg/ml or TLR2/4 ligand: Pam3CSK4, 200ng/ml. After 16 hours of incubation 
at 37º C, supernatants were aspirated and stored at -80º C, while the cells were lysed di-
rectly in the cell culture plate, and cell lysates stored at -80ºC.
Antibodies	and	flow	cytometry	(Article	III)
To identify which cells that had been activated by the stimulation using capsular saccha-
rides or cell wall polysaccharide as described above, the following labeled fluorochrome 
conjugated monoclonal antibodies were used; anti-CD3-Pacific Blue, anti-CD56-PE, anti-
CD4-APC H7, anti-CD14-PerCP and anti-CD69-FITC. The antibodies were added to 50 
μl of stimulated blood and incubated in darkness for 20 min, in RT. Thereafter, a Coulter 
multi-Q prep was used to illuminate red blood cells and to fix and stabilize white blood 
cells. The remaining sample from the stimulated blood, which were not used in the above 
tests, was centrifuged and the supernatant was stored at - 20ºC. The cells were analyzed by 
flow cytometry. To identify lymphocytes and different subgroups of lymphocytes, FSC and 
SSC were used together with the antibody pattern for the respective cell types; CD3 (T-
cells), CD3pos CD4pos, CD3pos CD4neg, CD3pos CD56pos (NK-like T-cells) and CD3negCD56pos 
(NK cells). To identify monocytes, FSC and SSC were used together with CD14. Due to 
limitations in flow cytometry, we were not able to stain for CD8, instead the CD8pos cells 
were assumed to form the majority of CD3posCD4neg cells. In addition to the surface mark-
ers for cell lineages, CD69 expression was used as marker of cell activation. Data is pre-
sented as mean fluorescence intensity (MFI) for CD69 or relative MFI (MFI of CD69 for 
stimulated cells divided by MFI of CD69 for unstimulated cells).
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Quantification	of	secreted	cytokines/	inflammatory	mediators	(Article	III)
In Article III cytokines in the supernatant from stimulated cells were quantified using Cy-
tometric Bead Array (CBA). Cytokine specific antibodies coupled to micro-particles were 
incubated with the supernatant. Following the addition of an anti-cytokine antibody, the 
amount of the bound cytokine antibody could be measured using flow cytometry. 
In Article III, the concentrations of TNF, IL-8, IL-10 and IFN-ɣ in supernatants were ana-
lyzed.  Data was analyzed using cytometric bead array (CBA) flex set (BD, Franklin Lakes 
NJ, USA), a multiplex assay allowing simultaneous detection of several analysis in a small 
sample volume. The cytokines were detected using the Cytometric Bead Array (BD Bio-
sciences) software, in a FACS CantoTM II flow cytometer (BD), and analyzed with FCAP 
Array Software version 1.01 (Soft Flow, Inc, St. Louis Park, MN, USA). The inflamma-
tory mediators in Article IV; IL-1beta, IL-6, IL-8, IL-10, GM-SFS, TNF, CCL2, CCL5 and 
CXCL8 were analyzed in the CBA Magnetic Luminex Assay. The supernatants from the 
frozen cell stimulation experiments were thawed and diluted 1:2 before measured using the 
BioPlex 200 system, and data was analyzed using the Bio Plex Manager 6.1.
Analysis of gene expression (Article IV)
For the isolation of RNA, the Qiagen RNA easy Plus Micro kit was used, and for the sub-
sequent cDNA synthesis, the High Capacity cDNA Reverse Transcriptase Kit, with 12 ng 
RNA/sample. To investigate the selected gene expressions, real-time PCR was performed 
on a CFX 384 Touch thermocycler. Expression of TNF, IL-1 beta, IL-6, IL-10, GM-CSF, 
TLR2, TLR4, CXCL8 and HPRT1 were quantified using Taqman assay. HPRT, which is 
expected to be constantly expressed (a so-called housekeeping gene), were used as a refer-
ence. Expressions of CCL-2 CCL-5, CD80, CD86, SOCS-1, SOCS-2 and SOCS-3 were 
quantified with specific primers designed “in house”, while CD14 and CD16 were analyzed 
using Prime PCR SYBR Green Assay (BioRad). All the described gene expression tests 
applied the iTag Universal SYBR green supermix for detection.
Statistics (Article III and Article IV).
In Article III, non-parametric variance analysis was used for multiple comparisons of con-
tinuous data. The non-parametric Wilcoxon-signed rank test was used to test statistical dif-
ferences between two dependent observations. Descriptive statistics and graphical methods 
were used to characterize data. The study required tests of several hypotheses, where each 
hypothesis was analyzed separately and the occurrence of patterns and the consequences of 
the results were taken into account in the analysis. All analyzes were performed using the 
SAS system 9.3, (SAS Institute Inc., Cary, NC, USA) and 5, 1 and 0.1% levels were con-
sidered.
Graph Pad PRISM 5 was used for graphs (GraphPad Software, Inc., San Diego, CA, USA). 
P-values <0.05 were considered statistically significant.
In Article IV, gene expression and protein concentration was calculated by Graph Pad Prism 
5. Non-parametric methods including Wilcoxon, Kruskal-Wallis and Spearman’s rank test 
were used as indicated, and p-values <0.05 were considered statistically significant.
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Article I
Blocking	of	non-specific	binding
A specific ELISA was developed in order to study the binding of Streptococcus pneumoniae 
to two different proposed pneumococcal receptors, asialo-GM1 and lactotriaocylceramide. 
Initially problem with highly unspecific binding of the pneumococci directly to the 
microtiter plate was encountered. Using E. coli LPS for coating in microtiter plates before 
pneumococci application, this unspecific binding could be blocked. With successively 
increasing concentrations of LPS, the described unspecific binding decreased. This 
indicates that the unspecific binding was of hydrophobic nature.
Comparison	of	two	different	media
In order to investigate the unspecific binding of pneumococci further, two different dilution 
media were compared. Pneumococcal strain R36A was diluted in either TBS-BSA or 
in ordinary blocking buffer, respectively. The unspecific binding described above was 
eliminated using pneumococci diluted in blocking buffer. As a control experiment, blocking 
buffer was also investigated without bacteria, which yielded completely negative results.
Comparison	of	two	different	receptors
Binding of R36A to asialo-GM1 could be observed at coating concentrations from 1 µg/ml. 
Binding to lactotriaocylceramide was detected at concentrations of 10 µg/ml. The results 
show that both these receptors are able to bind pneumococci, but compared to asialo-GM1, 
approximately 10 times higher concentration of lactotriaocylceramide is required. For 
lactotriaocylceramide, the binding capacity was half of the binding capacity of asialo-GM1 
(Figure 3).
Binding	of	different	pneumococcal	strains	to	asialo-GM1
When testing different pneumococcal strains for binding to asialo-GM1, all tested strains 
bound; R36A, two strains with capsule (strain CCUG 6605 (type 19) and CCUG 2987 (type 
23) and a C mutant strain. However, each strain exposed a different degree of binding. The 
C mutant strain, which is characterized by a small capsule of CWPS, bound to a lower 
degree (Table 1).
RESULTS
Table 1. Bindning of pneumococcal strains to asialo-GM1 in ELISA. The bacteria were suspensed in 
PSM-buffer to OD 1,0. Bound bacteria were detected using a polyclonal pneumococcal antibody. The 
coating dose of asialo-GM1 was 20 µg/ml.
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Article II
Purification	and	characterization	of	CWPS
To characterize the structure with which the pneumococcal bacteria bind to asialo-GM1, 
the non-capsule pneumococcal strain R36A saccharides and proteins were separated by 
hot phenol-water extraction and purified by gel permeation chromatography. The resulting 
fractions from the Sephadex column were tested for binding to asialo-GM1 in ELISA, 
after which positive fractions were pooled and lyophilized. The freeze dried material was 
examined by nuclear magnetic resonance spectroscopy (NMR) and demonstrated good 
agreement with pure CWPS (22). In order to further confirm that the material purified 
indeed was CWPS, the material was also examined in Dot blot with an affinity purified 
rabbit monospecific antibody directed against an epitope containing sugar 2-acetamido-
4-amino-2,4,6-trideoxygalactose (46). This is a repeating structure of sugar in CWPS. 
Analysis of the material in SDS-page and Western blot with the monoclonal anti-
phosphorylcholine antibody yielded three to four bands in a step-like pattern. The bands 
had molecular weights between 20 and 30 kDa, the distance between the bands was about 
2.2 kDa and the main band exhibited a molecular weight of about 22 kDa.
Depending on the amount of material added to the gel, Western blot showed four to six 
bands with a monoclonal anti-phosforylcholine antibody or a polyclonal rabbit anti-
pneumococcal serum (49). To investigate whether CWPS contained any oligopeptides that 
would affected its binding to asialo-GM1, the purified material was treated with protease-K, 
urea and guanidine-HCL. No effect of binding capacity could be noted after this treatment 
(Figure 4).
Figure 3. Comparison of the binding of Streptococcus pneumoniae, strain R36A, to two suggested 
receptor structures in an enzyme immunoassay. (□) Represents asialo-GM1 and (■) represents 
GlcNAcβ1-3Galβ1-4Glcβ1-ceramid.
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Binding of solubilized surface components
By heat treatment of R36A at 65° C for 40 minutes, surface components, termed “heat 
extract”, were extracted. The extract was examined in ELISA where the components 
that bound to pre-coated asialo-GM1 could be detected both with polyclonal antibodies 
as well as with monoclonal antibodies to phosphorylcholine. The latter indicates that 
the component in the heat extract that binds to asialo-GM1 contains CWPS. After heat 
extraction, the bacteria could still bind to asialo-GM1 in ELISA. 
Bacteria harvested in different growth phases were investigated in regards to binding 
capacity. Bacteria harvested in log phase, growth phase, and stationary phase were 
compared. At equal cell concentrations, the resulting signal was higher in bacteria harvested 
in the log phase. This indicates that the bacterial surface exposes more binding material 
during the log phase. Heat extract from R36A was examined in SDS-PAGE and Western 
blot. Pure CWPS was used as control in the experiment. CWPS was identified with a 
monoclonal anti-phosphoryl antibody. The band pattern for the heat extract in Western blot 
with the monoclonal anti-phosphoryl antibody corresponded well to the band pattern from 
pure CWPS.
To further characterize the binding material, the extract was subjected to separation by 
SDS-PAGE after which the gel was cut into five different horizontal discs. Each disc was 
eluted in PBS and subdivided into two portions. The eluate was then tested in ELISA for 
binding to asialo-GM1 and also examined in SDS-PAGE and Western Blot to determine the 
molecular weight of the substances that bound to asialo-GM1.
Samples exposing binding activity to asialo-GM1, as detected with the polyclonal anti-
pneumococcal antibody, were those containing a phosphorylcholine determinant. No 
reduced binding to asialo-GM1 in ELISA was observed when protease K-treated extract 
was analyzed.
Figure 4. Binding of purified pneumococcal C-polysaccharide (PnC) to asialo-GM1 in ELISA. 
Detection of bound PnC was performed using an anti-pneumococcal polyclonal antibody.
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Phosphorylcholine residues and binding of CWPS
To further investigate the phosphorylcholine in CWPS and its importance for binding to 
asialo-GM1, R36A was cultured in a defined medium in two different variants; one batch 
containing choline while choline was substituted with ethanolamine in the second batch. 
Bacteria grown in the choline containing medium bound to asilao-GM1 in Elisa, while 
ethanolamine-derived bacteria did not bind. Bacteria and heat extracts from both cultures 
were also investigated in SDS and Western Blot. Choline containing bacteria and extracts 
showed band patterns as for CWPS with a monoclonal anti-phosphoryl choline antibody. 
Ethanolamine containing bacteria exhibited no such bands when exposed to the same 
Figure 5. Pneumococcal cells (strain R36A) were grown in defined media containing either choline 
or ethanolamine. (a) Bacterial cells were tested for binding to asialo-GM1 in ELISA. —□—: bacteria 
grown in choline-containing medium; —♦—: bacteria grown in ethanolamine-containing medium. For 
detection anti-pneumococcal polyclonal antibody was used. (b and c) Bacteria and undiluted extracts 
were run in SDS-PAGE and analysed by Western blot. Extracts were obtained by heat-treatment of 
a suspension of bacterial cells (OD 1.0 at 600 nm). (b) Western blot using an antiphosphoryl choline 
monoclonal antibody. (c) Western blot using an antipneumococcal polyclonal antibody. M: molecular 
weight marker; C: bacteria grown in choline-containing medium; E: bacteria grown in ethanolamine-
containing medium; CE: extract from bacteria grown in choline-containing medium; EE: extract from 
bacteria grown in ethanolamine-containing medium.
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antibody. However, both choline and ethanolamine cultured bacteria exhibited bands in 
Western Blot with polyclonal anti-pneumococcal antibodies (Figure 5).
Article III
CD69 expression after stimulation of whole blood
CD69 was used as a marker for activated leukocytes in stimulation experiments where 
whole blood was stimulated with CWPS and with three different capsule types from 
pneumococci; type 3, type 9 and type 23. Leukocyte cell types; CD4pos T-cells, CD4neg 
T-cells, NK-like (CD56pos) T-cells, NK cells and monocytes were analyzed for CD69 
expression after 4 or 12 h stimulation respectively. The capsules activated all cell types 
analyzed, but to a different extent, as shown for NK-cells in Figure 6. Following CWPS 
stimulation, NK cells had the highest CD69 expression (measured as relative MFI value). 
The second highest values were observed in CD56pos T-cells, followed by monocytes 
and CD4neg T-cells and finally CD4pos T-cells (Figure 7). Overall, the CWPS stimulated 
immune cell subsets to a higher degree than observed for the capsules. However, CWPS 
is not included in the statistical comparisons since it was used as positive control. Instead, 
the ability of the three capsules to stimulate the different leukocyte cell types after 4 
respective 12 h was compared. Regarding the pneumococcal capsules, type 23 stimulated 
the leukocytes strongly, followed by type 9 and type 3. There was a statistically significant 
difference observed between type 3 and type 23 in eight out of nine (8/9) tests and this 
was also observed between type 3 and type 9 in seven out of nine (7/9) tests. However, 
between type 9 and type 23, there was only a significant difference observed in three of 
nine (3/9) tests. The results were consistent for 4 h and 12 h stimulation, with only minor 
Figure 6. Cell activation was assessed as expression of CD69 by flow cytometric analysis. The 
histograms show results after whole blood of healthy controls was stimulated by CWPS and three 
different pneumococcal capsular polysaccharides. The figure depicts CD69 expression on NK cells 
where (a) shows CWPS and negative control, (b) shows type 3, type 9 and type 23 capsules and negative 
control and (c) shows LPS and negative control. CWPS; pneumococcal cell wall polysaccharide, LPS; 
lipopolysaccharide. (Number of individuals included, N = 9).
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Figure 7. CD69 expression in cell subsets. CD69 expression was determined as a measure of cell 
activation after in vitro stimulation. Whole blood from healthy non-pneumococcal vaccinated subjects 
was stimulated for 4 h (Figure part A, N = 8) with pneumococcal C-polysaccharide (CWPS) and 
pneumococcal capsular polysaccharides type 3, type 9 and type 23. Unstimulated whole blood was 
used as negative control and stimulation with LPS as positive control (data not shown). Graphs show 
CD69 expression in stimulated versus unstimulated cells, expressed as relative MFI, for the respective 
cell subsets indicated above each graph. Statistical comparisons were only carried out between the three 
capsular polysaccharides (type 3, type 9 and type 23).  
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variations observed.
Quantification	of	secreted	cytokines
Supernatants of unstimulated cells and cells stimulated with; CWPS, type 3, type 9 or type 
23 pneumococcal capsules were compared for cytokine release. Stimulated cells released 
IL-8, TNF, IL-10 and IFN-ɣ. Exceptions from this were seen in type 3 for IFN-ɣ and IL-
10, and in type 9 for IFN-ɣ. Stimulation of cells with CWPS showed that the IL-8 cytokine 
concentration was the highest, followed by IL-10, TNF and INF-ɣ. Stimulation with the 
capsules type 9 and type 23 yielded the highest concentration of IL-8, which was followed 
by TNF, IL-10 and IFN- ɣ. The cytokine pattern for the type 3 capsule gave rise to a higher 
value of IL-10 than TNF, which is similar to the described CWPS pattern.
The type 9 and type 23 capsules stimulated cytokine release to a much greater extent than 
what was observed for the type 3 capsule. There was a significant difference in the release 
of cytokines IL-8, TNF and IL-10 observed between capsule type 3 versus type 23 and 
type 9 respectively. Between the type 9 and type 23 capsules no significant difference was 
observed. There were no significant differences observed from stimulated cells exposed to 
the different capsules in regard to IFN-ɣ.
Article IV (manuscript)
This study includes two different groups of healthy subjects, smokers and nonsmokers, 
with normal lung function measured as FEV1.0 and without any signs or symptoms of 
airway disease, lung disease or inflammatory disease, and with identical distribution of sex 
and age. Although spirometry did not show any signs of obstruction, the median FEV1.0 in 
smokers was reduced compared with non-smokers.
CWPS from S. pneumoniae induces	 gene	 expression	 of	 pro-inflammatory	mediators	
from monocytes
The ability of pro-inflammatory mediators to induce gene expression and secretion of 
inflammatory mediators in isolated blood monocytes after stimulation with cell wall 
polysaccharide, CWPS, from Streptococcus pneumoniae was investigated. 
Monocytes were isolated from peripheral blood collected from twenty-one healthy subjects 
(11 smokers and 10 non-smokers), and the gene expression and secretion of inflammatory 
mediators were analyzed after stimulation with pneumococcal cell wall polysaccharide 
(CWPS), and other TLR ligands.
The results show that the gene expression of the cytokines IL-1β and IL-6, and the 
chemokines CCL2 and CXCL8 was induced by CWPS stimulation. Furthermore, the 
analysis showed that the expression was dependent on the concentration of CWPS used (1 
or 10 µg/ml) and that the higher concentration (10 µg/ml) induced a significant increase 
compared to unstimulated monocytes. Therefore, the subsequent analyses in this study were 
performed using a CWPS concentration of 10 µg/ml.
Pro-inflammatory	gene	expression	in	monocytes	and	in	NK-cells	after	stimulation	with	
the TLR ligands CWPS, Pam3CSK4 and LPS
TLR2 ligand CWPS, TLR1/2 ligand Pam3CSK4 and TRL4 ligand LPS were all exam-
ined for their capacity to elicit gene expression of pro-inflammatory mediators and co-
stimulatory molecules in isolated monocytes from twenty-one healthy subjects. Results 
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were compared to the findings in unstimulated monocytes (Figure 8). The concentrations of 
Pam3CSK4 and LPS used in the study were previously known to induce a pro-inflamatory 
response in monocytes. As expected all three ligands significantly elevated the pro-inflam-
matory cytokines IL-1β, IL-6, as well as the chemokines CCL2 and CXCL8, in monocytes. 
Gene expression of the co-stimulating molecules CD80 and CD86 was also regulated by 
TLR stimulation of monocytes. In the present experiments, all TLR ligands upregulated 
CD80, with the strongest upregulation shown for LPS, followed by Pam3CSK4 while 
CWPS elicited the weakest response. In contrast, LPS downregulated CD86, while the 
TLR2 ligands did not affect this gene expression after stimulation. 
A previous study (Article III) indicated that CWPS activates NK-cells. Thus, isolated NK-
cells from peripheral blood were also stimulated with the TLR ligands CWPS, Pam3CSK4 
and LPS. All three ligands upregulated CXCL8 expression significantly, but no other signifi-
cant increase in gene expression was detected for the other inflammatory mediators, IL-1β, 
IL-6, TNF, CCL2, CCL5, included in the study.
Cytokine and chemokine secretion in monocytes after stimulation with TLR ligands
To analyze the secretion of pro-inflammatory mediators, the concentration of selected cyto-
kines and chemokines was analyzed in the cell supernatant of stimulated monocytes from 
twenty-one healthy individuals. The TLR ligand CWPS induced secretion of IL-1β, IL-6, 
TNF, CCL2 and CXCL8, but not of GM-CSF or CCL5. The TLR ligands Pam3CSK4 and 
LPS both induced cytokine secretions of all the cytokines and chemokines investigated; 
IL-1β, IL-6, TNF, GM-CSF, CCL2 and CXCL8. The secretion of CCL2 and CXCL8 was 
strongly induced by all TLR ligands, whereas CCL5 secretion was not affected by TLR 
stimulation. 
Cigarette smoke is a well-known risk factor for infection with Streptococcus pneumo-
nia both systemically and in the airways. In order to investigate differences in the TLR-
response, including the response to CWPS, based on cigarette smoking habits, the cohort 
was divided two groups; eleven non-smokers and ten smokers. They were then investigated 
for differences in the expression of proinflammatory mediators and secretion of cytokines 
and chemokines. The groups showed no significant difference in cytokine or chemokine 
production when the monocytes were incubated with medium alone (unstimulated). On the 
other hand, there was a difference detected between non-smokers and smokers in stimulated 
monocytes. Stimulation with Pam3CSK4 reduced CCL5 secretion significantly in smok-
ers, while LPS stimulation instead resulted in a significant increase in CXCL8 secretion in 
smokers. CWPS stimulation however did not induce any difference in the secretion of cyto-
kines or chemokines in the supernatant between non-smokers and smokers.
Gene expression of mediators in isolated monocytes from smokers and non-smokers 
The groups were also analyzed for differences in gene expression after stimulation with 
the TLR ligands CWPS, Pam3CSK4 and LPS. In unstimulated isolated monocytes, no dif-
ference was found in the expression of selected genes between non-smokers and smokers. 
However, monocytes from smokers stimulated with CWPS induced a stronger inflamma-
tory response, compared to cells from non-smokers. This difference was significant for the 
expression of IL-6, TNF, CCL5 and CD80. Monocytes stimulated with Pam3CSK4 induced 
a significantly stronger TNF expression in smokers compared to non-smokers, whereas 
LPS-stimulated monocytes from smokers expressed a similar, but not significant, trend 
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(Figure 9). The gene expression of CXCL8 in NK-cells exhibited no significant difference 
between smokers and non-smokers. Following LPS stimulation of TLR, the cytokine ex-
pression between smokers and non-smokers differed which may indicate a specific regula-
tion of gene expression. While the expression of inflammatory mediators was higher in cells 
from smokers, no significant correlation was observed between the higher gene expression 
and smoking habits. 
Gene expression for TLR2 and TLR4 in non-smokers and smokers
The study also analyzed whether the gene expression of TLR2 and TLR4 were associated 
with the difference in the gene expression for the inflammatory mediators observed be-
tween smokers and non-smokers. Monocytes incubated in medium, i.e. unstimulated, were 
analyzed to approximate the gene expression seen in vivo. In unstimulated cells there were 
no differences observed in gene expression for TLR2 and TLR4 between non-smokers and 
smokers. 
Monocyte	marker	CD14	are	expressed	differently	in	smokers	and	non-smokers
The surface markers CD14 and CD16 are used to identify and characterize peripheral blood 
monocytes. Analysis of the gene expression for the surface markers showed a significantly 
reduced gene expression of CD14 in smokers, but no difference in the gene expression for 
CD16 between nonsmokers and smokers. In unstimulated monocytes, there was a positive 
correlation of gene expression for both CD16 and TLR2 with the gene expression of CD14, 
i.e. individuals with high CD14 expression also showed a high expression of TLR2 and 
CD16.
Expression of immune-regulatory molecules induced by TLR stimulation, in monocytes 
of smokers and non-smokers 
Immune-regulatory signaling can be affected by TLR stimulation. The monocytes were 
therefore investigated both in terms of gene expression and secretion of anti-inflammatory 
cytokine IL-10, in non-smokers and smokers, respectively. Secretion of anti-inflammatory 
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Figure 3. Öckinger et al
Figure 9. Stimulation with TLR-ligands induces a different response in monocytes between non-
smokers and smokers. Gene expression of selected cytokines, chemokines, and co-stimulatory 
molecules was measured by qPCR in isolated peripheral blood monocytes, after stimulation with LPS 
(100 ng/ml), CWPS (10 µg/ml), Pam3CSK4 (200 ng/ml) for 16 h. Gene expression presented as fold 
change relative to the unstimulated cells, for each individual. Bars indicate mean, and error bars SEM. 
Statistic calculated in Mann Whitney test, for each stimulation gene. *: p<0,05, **: p<0,01.
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IL-10 was observed after stimulation with LPS and Pam3CSK4, while IL-10 concentration 
was unchanged after CWPS stimulation. CWPS stimulation of isolated monocytes induced 
downregulation of the gene expression of IL-10 which was significantly more pronounced 
in non-smokers versus smokers. 
Suppressors of cytokine signaling (SOCS) are a family of immunoregulatory compounds. 
To investigate differences between non-smokers and smokers, gene expression of SOCS-
1, SOCS-2 and SOCS-3 was investigated in isolated monocytes (unstimulated cells and 
after TLR stimulation). In unstimulated cells from smokers, the analysis indicated a lower 
expression of SOCS-1 and SOCS-3, compared to non-smokers. Expression of these two 
genes, correlated positively with CD-14 expression. Expression of SOCS-1 is downregu-
lated after TLR2 stimulation compared to what is observed in unstimulated cells.  
When comparing the groups of smokers and non-smokers, results show a SOCS-1 down-
regulation only in cells obtained from the non-smokers. SOCS-2 expression is upregulated 
by LPS, while SOCS-3 expression is upregulated by either LPS or Pam3CSK4, however, 
no difference between smokers and non-smokers was detected. SOCS-1 and SOCS-3 cor-
related positively with the gene expression for CD14.
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DISCUSSION
Article I  
Glycoconjugates on lung and epithelial host cells constitute a common binding site for 
pathogenic bacteria (24). The cell receptors, GalNAcbeta1-4Gal, GlcNAcbeta-1-4Gal are 
common binding sites for various bacterial pulmonary pathogens, including Streptococcus 
pneumoniae (48, 49). 
When the present project was started, two different disaccharides from glycolipids had been 
proposed as epithelial cell receptors for the binding of pneumococci (48, 50). The bind-
ing sites on the glycolipids were proposed to be the disaccharides GlcNAcβ1-3Gal and 
GalNAcβ1-4Gal. Previous studies of these receptors were performed by different methods. 
One of the earlier described methods included an inhibition test to determine the pneumo-
coccal binding specificity to nasopharynx cells while yet another method detected the bind-
ing of bacteria to ganglioside receptors that had been separated in thin layer chromatogra-
phy. Using the described tests, the binding affinities of pneumococci to the various recep-
tors were difficult to compare. In the thin layer chromatography system, no pneumococci 
binding could be detected to GlcNAcβ1-3Gal due to restrictions in receptor concentrations. 
This was not the case for GalNAcβ1-4Gal affinity, which exhibited good pneumococcal 
binding in the test (48). Neither were these two different methods comparable with regard 
to the amount of receptors needed for pneumococcal adhesion. When using the thin layer 
chromatography method, concentrations of less than 10 μg/ml GalNAcβ1-4Gal could easily 
bind bacteria (48) while for the epithelial cells inhibition test, 100 μg/ml of lactoneotetrao-
cylceramide containing GlcNAcβ1-3Gal was needed to gain a 50% inhibition of pneumo-
cocci adhesion to epithelial cells (50).
In the current study, the aim was to directly compare pneumococcal binding to the differ-
ent receptors using the identical method for both receptors. For this reason an ELISA was 
developed where the two receptors GlcNAcβ1-3Gal and GalNAcβ1-4Gal were coated. 
Initially, there was a major problem with non-specific binding of the pneumococci to the 
plastic in the ELISA plates. During the development of this ELISA, it was found that the 
non-specific binding could be markedly reduced by coating the plastic surface with the gly-
colipid receptors.
In addition, a dose-dependent inhibition of the non-specific pneumococcal binding could 
then also be achieved in the ELISA plates when pre-coated with different amounts of LPS, 
indicating a hydrophobic attachment as the cause for pneumococci non-specific binding. 
By addition of an anti-hydrophobic solution to the test system, this unspecific binding was 
effectively reduced, without affecting the ELISA otherwise. The described ELISA measures 
the binding of pneumococci to the purified receptor glycolipids, asialo-GM1 and lactotria-
ocylceramide, without any interference of other receptors.
Eventually, the results gained showed that pneumococci are capable of binding to the two 
proposed receptors GalNAcβ1-4Gal and GlcNAcβ1-3Gal, but with distinct different affini-
ty. The bacteria bind with higher affinity to GalNAcβ1-4Gal than to GlcNAcβ1-3Gal, which 
is consistent with previous results.
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Strains of the bacteria Escherichia coli have also been shown to bind to the two receptors 
GalNAcβ1-4Gal and GlcNAcβ1-3Gal (51). As in the case of pneumococci, the E. coli 
strains bind stronger to GalNAcβ1-4Gal and with lower adherence to GlcNAcβ1-3Gal. 
Mutants of these E. coli strains which are negative in binding tests to an enteropathogenic 
LA cell line simultaneously showed significantly reduced binding to asialo-GM1. The 
α-streptococci bacteria, which are closely related to Streptococcus pneumoniae, also bind to 
more than one receptor with different affinities (52). In the present publication, the capsule 
did not prevent adhesion. This was later confirmed by Geelen et al., using the same pneu-
mococcal strain (53). 
GalNAcβ1-4Gal is identified in lung tissue. It is usually sialylated. Many viruses and also 
pneumococci contain the enzyme neuraminidase that possess the ability to cut away the 
sialic acid located on glycoconjugates of the host cell, thereby exposing previously hidden 
receptors (54). Pneumococcal pneumonia frequently occurs as a complication after viral 
infections in the upper respiratory tracts, which in part may be explained by the described 
ability of viral neuraminidase to expose the receptor (55). Neuraminidase enzymatic capac-
ity also has the ability to reduce mucus viscosity which has been shown to further facilitate 
adhesion, colonization and biofilm formation on the host cell surface (7, 56).
GlcNAcβ1-3Gal has been isolated in breast milk. The receptor inhibits the binding of pneu-
mococci to human pharyngeal and buccal epithelial cells, which may indicate that this re-
ceptor molecule may coat the outside of the bacteria resulting in a reduction of the binding  
to the epithelial cells (50). However, it should be noted that the presentation of the receptor 
molecule used in solution versus the presentation in solid phase may differ (57).
Following the publication of this work, several additional pneumococcal receptors on host 
cells have been described and examined. These include the platelet activating factor recep-
tor (PAFr) found on epithelium in lung, bronchial and alveolar tissue, as well as in other 
cell types. Pneumococci can bind to PAFr, and be transported through the cell into the 
blood stream (24, 58). Streptococcus pneumoniae has also been shown to bind to the poly-
meric immunoglobulin receptor (pIgR) involved in the adhesion of pneumococci to human 
nasopharyngeal cells (59). The receptor plgR is also expressed on brain endothelial cells, 
and Iovino et al. found that pneumococci adhere to this receptor in the blood brain barrier 
(BBB) endothelium (60). Another receptor that is important for pneumococcal adhesion 
and invasion is the Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1) receptor 
also expressed on BBB endothelial cells, which mediates pneumococcal adhesion (61). The 
Laminin receptor (LR), found on endothelial cells also has the ability to bind Streptococcus 
pneumoniae. Finally, pneumococcal surface proteins can bind to Vitronectin (62).
Article II
Pneumococci adhere to human host cells through the interaction with several receptors (53, 
63), including glycolipid receptors. It has been shown that pneumococci bind to the surface 
glycolipids of nasopharynx cells containing GlcNAcβ (1-3) Gal, as well as to lung and 
vascular endothelial cells containing GalNAcβ (1-4) Gal and GalNAcβ (1-3) Gal (48, 50, 
64). An ELISA for the detection of pneumococci binding to asialo-GM1, which contains 
GalNAcβ (1-4) Gal has been developed and described in Article I (65). In a previous study 
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(Article I) it was shown using ELISA that both capsulated and uncapsulated pneumococci 
bind to asialo-GM1, which contains GalNAcβ (1-4) Gal (65). In addition, pneumococcal 
binding to type II lung cells (LC) was not prevented by different capsule types (64).
The aim of the current study (Article II) was to investigate the pneumococcal ligand 
responsible for the binding to asialo-GM1. Earlier reports indicated that pneumococcal 
binding to endothelial cells could be inhibited by soluble cell wall components from 
pneumococci. Since the maximum inhibition from soluble cell wall components described 
was only 60%, it could be assumed that there are additional adhesion mechanisms involved  
(53). The results in study II indicate that purified CWPS binds to asialo-GM1. 
CWPS constitutes the major cell wall teichoic acid of the pneumococci. It is covalently 
bound to the cell wall and exposed on the pneumococcal surface (66). CWPS consists of 
ribitol-containing, repeating pentasaccharide units with two phosphorylcholine substituents 
linked to the acetylated galactosamine residues (22).
In the present study we show that purified CWPS bind in a dose-dependent manner to 
asialo-GM1 and that protease K treatment does not affect adhesion, i.e., protein components 
are not involved in the detected binding. Together this indicates that CWPS most likely 
is involved in the binding to the receptors asialo-GM1 and asialo-GM2, both containing 
GalNAcβ (1-4) Gal. Following heat treatment of pneumococcal bacteria at 65° C, material 
(”heat extract”) is released. This “heat extract” subsequently adhered to asialo-GM1 in 
ELISA. The substance which adhered to asialo-GM1 reacted with both a rabbit anti-
pneumococcal polyclonal antiserum and an anti-phosphorylcholine monoclonal antibody 
(46). This indicates CWPS involvement in the binding to asialo-GM1. The heat extract was 
also separated on SDS PAGE from which fractions were eluted. It was shown that the SDS-
PAGE fraction adhering to asialo-GM1 could be identified in Western blot as CWPS using a 
monoclonal anti-phosphorylcholine antibody. In the described experiments, treatment with 
protease K did not affect adhesion. 
“Heat extract” and purified CWPS separated on SDS PAGE and analyzed in Western blot 
showed identical band patterns (unpublished data). The band pattern indicated different 
chain lengths of CWPS where each band contained different numbers of repeating units. 
Molecular weights for CWPS were estimated to range between 20-30 kDa, which cor-
responds well to the value of 26.4 kDa previously reported (67). The distance between the 
individual CWPS bands corresponded to approximately 2.2 kDa, which is believed to rep-
resent the difference in molecular weight for more than one repeating unit. 
It has previously been shown that purified CWPS may be linked to fragments of pepti-
doglycan (68), which could explain the obtained results. However, in the present study 
the CWPS identity was confirmed by H-NMR as well as in Dot blot using a monoclonal 
antibody with specificity against the repeating units specific to the 2-acetamido-4-amino-
2,4,6-trioxygalactose epitope. This epitope is independent of the phosphorylcholine moiety 
(46). When culturing pneumococci under laboratory conditions, choline may be replaced 
with ethanolamine or other amino alcohols in the culture medium. Ethanolamine is then 
incorporated where choline usually is situated (47). When ethanolamine was incorporated, 
the pneumococci lost their ability to transform and autolys. After cell division, the cells are 
associated with each other (47). In the case where choline was replaced by ethanolamine, 
these bacteria did not bind to asialo-GM1. This indicates that the presence of phosphoryl-
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choline residues is necessary for the binding of pneumococci to asialo-GM1. 
Both bacteria and “heat extract” from bacteria adhered to asialo-GM1 when the pneumo-
cocci were cultured in choline. The results show that CWPS, containing phosphorylcholine, 
is the ligand responsible for pneumococcal binding to the receptor asialo-GM1.
Interactions between carbohydrates and bacteria have been described previously. In Pseu-
domonas aeruginosa, LPS and pili specifically bind to glycolipid asialo-GM1 (69). The 
outer protein membrane of Chlamydia trachomatis is glycosylated and binds to the glycan 
of HeLa Cells. This binding is inhibited by D-galactose, D-mannose and N-acetylglucos-
amine, which indicates that the glycan portion of the outer membrane protein is involved 
(70).
Apart from asialo-GM1 it is known that phosphorylcholine is involved in binding to yet 
another receptor, the platelet activating factor receptor, PAFr.  As revealed by the name, 
this receptor binds the platelet activating factor, PAF, a common cytokine. PAFr is found in 
lung, vascular and brain cells as well as in leukocytes (24). PAF, like pneumococci, exposes 
phosphorylcholine and both PAF and pneumococci bind to PAFr through the interaction of 
phosphorylcholine. The magnitude of interaction with PAFr may be affected by the amount 
of phosphorylcholine present in the pneumococcal cell wall (71). Via PAFr, the pneumo-
coccus is taken up into an intracellular vacuole and by this mean transported to the blood 
stream (58). It has been shown that the expression of PAFr may be induced on lung cells 
and vascular endothelial cells following cytokine stimulation (24, 53). The choline replace-
ment by ethanolamine in pneumococci decreased the binding to the PAF receptor (24).
Streptococcus pneumoniae binds to human cells through the action of several ligands. CbpA 
is one of the family members of the choline binding proteins (Cbp), anchored to phosphor-
ylcholine on the cell wall teichoic acid (CWPS). Binding of pneumococcal CbpA to the 
plgR receptor on human nasopharyngeal cells, generates uptake of the bacterium into the 
cell (59). Furthermore, CbpA is able to bind to Laminin receptor, LR, on human vascular 
endothelial cells (72). CbpA also bind to human Vitronectin (73). Other pneumococcal pro-
teins also function as adhesins, for example, other choline binding proteins (74) and pilus 
proteins (7, 75). Biofilm formation is reported to be mediated by Pneumococcal serine-rich 
repeat protein (PsrP) (76). 
Article III
The aim of this study was to analyze the activation of immune cells as well as cytokine 
secretion after stimulation with Streptococcus pneumoniae saccharides, in blood from 
healthy individuals. The saccharides used for the study were C-polysaccharide (CWPS) 
and three different capsular saccharides; serotype 3, serotype 9 and serotype 23. All 
these capsules are included in the 23-valent pneumococcal vaccine and in the conjugated 
vaccines, with the exception of the 7-valent conjugated vaccine where serotype 3 is not 
included. The immune cells analyzed for activation (measured as CD69 expression) were 
monocytes, NK-cells, CD4pos T-cells, CD4neg T-cells and CD56pos T-cells.
The cytokine secretion in the supernatant was assayed for TNF, IL-8, IL-10 and IFN-ɣ. 
All immune cell subsets analyzed were activated by stimulation of whole blood with 
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both CWPS and all of the capsules, with few exceptions. The responding immunocellular 
activation was, however, of varying amplitudes. The activation response from the 
stimulation was strongest for NK-cells, NK-like T-cells (CD56pos T-cells) and monocytes. In 
contrast, CD4neg and CD4pos T-cells exhibited the lowest degree of activation. 
The three types of capsules differed from each other in their ability to induce immune cell 
activation: Type 23 achieved the highest activation, followed by type 9 while the lowest 
degree of activation after stimulation was observed with capsule type 3. 
The same pattern was observed for cytokine secretion post-stimulation, in that the highest 
concentrations were induced by type 23. Again this was followed by type 9 capsules while 
the lowest values were observed from type 3 capsules.  
In this study, CWPS activated monocytes, T-cells and NK-cells to a higher degree, 
compared to the capsules. CWPS is a teichoic acid (22) which is a known TLR2 ligand 
(77). TLRs recognize conserved patterns of different pathogens and are a part of the innate 
immune system. CWPS has a pattern of positive and negative charges in repeating units 
and has a so-called zwitterionic polysaccharide (ZPS), which enables direct stimulation of 
T cells (78). ZPS also act as ligands for TLR2 (79). CWPS induces B-cell proliferation by 
the identical subunits capable of crosslinking the B cell receptor. The degree of activation 
(CD69 expression) post stimulation was highest in the NK-cells. NK-cells are capable of 
stimulating B-cells to antibody release and isotype switch, which can be observed after 
vaccination against pneumococci (80-82). It has also been shown that no isotype switch of 
antibodies occurs in the absence of NK-cells (82).
Regarding analysis of CD8pos T cells, FACS limitations prohibited us from including anti-
CD8 in the staining protocol and we therefore measured the activation of the CD4neg T-cell 
subset. However, in parallel experiments we found that almost 90% of CD4neg T-cells were 
CD8pos, indicating that both CWPS and the three capsules activated CD8pos cells. 
It has been shown that CD8pos T-cells are important for the protective pneumococcal anti-
body response (83). Antibodies to pneumococcal polysaccharides cannot be produced in 
mice lacking CD8pos (84).
Exposure of pneumococcal capsule type 23 activated all the investigated immune cells. 
This response was followed by type 9 and finally by type 3 that elicited the smallest degree 
of immune response among the studied capsules. 
Capsule polysaccharides are known to be B-cell antigens. Therefore they are used in vac-
cines to induce protective antibodies. However, since the capsular saccharides are not TLR 
ligands, the mechanism behind this immune cell activation is unclear. Direct stimulation oc-
curs in cells expressing TLR, which are monocytes, NK-cells (85), and also NK-like T-cells 
(86), but not CD56neg CD4neg T-cells or CD4pos T-cells. However, the serotype 1 pneumococ-
cal capsule (not used in this study) is the only capsule capable of activating TLR. Studies 
indicate that there might be a small amount of CWPS even in highly purified capsular poly-
saccharides from pneumococci (87). In the present trials, therefore it cannot be completely 
excluded that CWPS might be involved in activation and cytokine secretion. The amount 
of CWPS bound in the different pneumococcal capsule types may vary. Furthermore, the 
repeating units in CWPS may either contain one or two phosphorylcholine residues (88). In 
summary, the mechanism behind capsule-induced activation of various immune cell subsets 
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remains to be clarified. The capsules generate antibody production by crosslinking to B-cell 
receptors. The antibodies elicited by the capsules have been shown to protect against fatal 
pneumococcal infections. 
Today there are two different types of Streptococcus pneumoniae vaccines on the commer-
cial market. One of these products is a saccharide vaccine containing 23 different Strep-
tococcus pneumoniae capsules. The other commercially available product is a conjugated 
vaccine, where the capsular saccharides are attached to a protein. This vaccine contains 
either seven, ten or thirteen different capsular saccharides. In the body, after injection, the 
protein is degraded into peptides which are presented by MHC class II molecules on B-
cells. These peptides are presented to T-cells, which are activated and start to proliferate as 
well as differentiate into effector cells that can provide B-cell help, thereby they generate 
differentiation and production of both B and T memory cells. In this conjugated vaccine, T-
cell cytokines contribute to inducing various immunoglobulin (IgG) subclass patterns (89). 
The T-cell cytokine profile and IgG subclass response are dependent on the pneumococcal 
serotype (89). The capsular (non-conjugated) saccharide vaccine is also able to induce an 
immunoglobulin class switch from IgM to IgG, which would not be expected from a T-cell 
independent antigen. This could indicate that the different capsular saccharides may have 
different ability to induce immunoglobulin class switch via T-cells, NK-cells and mono-
cytes. The capsule composition in the conjugated vaccine may affect the levels of the pro-
tective antibodies after vaccination. Pneumococcal pulmonary inflammation can be associ-
ated with difficulty to increase the antibody concentration against specific serotypes after 
vaccination (90).
The results from the cytokine release experiments exhibited a pattern consistent with 
the immune cell activation measured as CD69 expression, i.e., CWPS induced cytokine 
release to the highest extent (with the exception of IL-8 where type 9 and type 23 were 
more potent), followed by capsule type 23 and in a descending scale type 9 and type 3. 
The results show that the capsules differed in their ability to trigger cytokine release after 
in vitro stimulation of whole blood. The cytokines included in the study were chosen in 
order to analyze a broad spectrum of leukocyte functions, albeit with a limited number of 
cytokines
In the study of whole blood stimulation, TNF most likely activated a variety of cells, such 
as monocytes, neutrophils, CD4pos T-cells and NK-cells. TNF is known to be involved in 
acute phase reactions and has many proinflammatory effects. 
INF-ɣ has been shown to be produced by activated T-cells and NK-cells and in turn stimu-
lates macrophages, leading to increased cytokine synthesis, increased phagocytosis and 
increased antigen presentation. IL-8 may be produced by monocytes and attracts neutro-
phils. IL-10 can be produced by T-cells and monocytes and also additional cells. It is an 
anti-inflammatory cytokine that inhibits e.g. T-cell responses. In vivo, pneumococcal com-
ponents have been shown to be capable of activating immune cells to release cytokines, for 
example macrophages. The ability to induce IL-10 differs between the different pneumo-
coccal capsules. Increased IL-10 may have a negative effect on the host immune response 
to vaccination.
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Generally, when evaluating the effect of vaccination, the overall IgG concentration is mea-
sured in serum. In the presented study a more detailed analysis is offered of how the differ-
ent immune cells and cytokine secretion patterns are affected by the various pneumococcal 
capsules and CWPS. As shown, CWPS activates the immune cells to a greater extent than 
the capsules. In turn, the capsules activate the immune cells differently. Cytokine release 
followed the same pattern as capsule-induced cell activation. As the three capsules studied 
were randomly selected, we believe that the proven differences in ability to stimulate im-
mune cells can be observed also for other capsules.
In the current study we have included analysis of blood monocytes, which may be expected 
to mirror aspects of the activation of other TLR-expressing cells, such as dendritic cells 
and macrophages in tissue, in conjunction with pneumococcal infection or vaccination.This 
study increases the understanding of how pneumococcal vaccination and pneumococcal ex-
posure affect human immune cells. There were observed variations in immune stimulation 
capacity among the various vaccine saccharide components. The results shown may partly 
explain variations in the effectiveness of the different capsule components of the vaccine.
Article IV (manuscript)
In this study, isolated monocytes and NK-cells were studied for their regulation of 
inflammatory mediators and other related immune mechanisms induced by LPS, 
Pam3CSK4, and CWPS from S. Pneumoniae. 
The results showed that stimulation with CWPS upregulates the gene expression of several 
pro-inflammatory key mediators, including IL-1β, IL-6, CCL2 and CXCL8, in a dose-
dependent manner. This finding is consistent with previous studies that have shown that 
NFkβ regulate the pro-inflammatory response of pneumococci via TLR2 (91). CWPS, 
a TLR2 ligand, was compared to other TLR ligands, e.g. LPS (TLR4) and Pam3CSK4 
(TLR2) respectively, for gene expression of pro-inflammatory genes in isolated monocytes. 
The results show that all the TLR ligands examined induce upregulation of IL-1β, IL-6, 
CCL2, CXCL8 and CD80 in monocytes, i.e. the ligands exhibit similar gene expression 
profile. In a previous study, we have shown that NK-cells are strongly activated after 
whole blood incubation with CWPS (92). Here we can confirm that CWPS induces gene 
expression for CXCL8 in isolated NK-cells, demonstrating a direct CWPS activation of the 
NK-cells, presumably via TLR2. However, the overall effect of CWPS activation of NK-
cells needs to be further investigated. 
We have also shown previously (92) that CWPS activate monocytes, after whole blood 
stimulation. We thus investigated if CWPS and the other TLR ligands induced secretion of 
inflammatory mediators, in isolated monocytes. All TLR ligands induced released of IL-
1β, IL-6, TNF, and the chemokines CCL2 and CXCL8 in the supernatant. This confirmed 
our previous finding of TNF secretion following CWPS stimulation in whole blood (92). 
One additional observation in the current study is that none of the TLR ligands induced 
detectable gene expression for TNF in monocytes, however TNF was nevertheless found 
in the supernatant. Since TNF is a known early response gene, it is thus likely that the 
upregulation of the TNF gene had already occurred, and again normalized, at the time of 
analysis. 
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We further studied the CWPS and the two other TLR ligands to analyze if they induced 
different responses between smokers and non-smokers. The results showed that the gene 
expression for TNF differed significantly between smokers and non-smokers. TLR ligands 
induced upregulation of the TNF gene in cells from smokers. After TLR2 stimulation 
the smokers remained unchanged. CWPS stimulation of isolated monocytes from smok-
ers showed higher expression of IL-6, CCL5 and CD80. Other TLR ligands, e.g. LPS and 
Pam3CSK4, exhibited similar but non-significant results in monocytes from smokers, with 
increased gene expression for inflammatory mediators. 
However, no other inflammatory mediators showed increased concentration in supernatants 
from smokers, compared to non-smokers, thus showing a distinct different pattern com-
pared to the gene expression. It is therefore likely that the separate mechanisms that regu-
late expression and secretion, are differently affected by cigarette smoking. Stimulation of 
monocytes with LPS induced a significantly higher concentration of CXCL8 in the superna-
tant of cells from smokers, compared to non-smokers, which could increase the recruitment  
of inflammatory cells.  
Between smokers and nonsmokers, there was no observed difference in gene expression of 
TLR2 and TLR4, although differences might not be directly associated with receptor expres-
sion. In contrast, a recently published study showed that smokers expressed higher levels of 
TLR2 after stimulation of PBMC, compared to non-smokers (93).  
CD14 expression differ significantly between smokers and non-smokers, but CD16 expres-
sion was unchanged. The surface markers CD14 and CD16 are used for the identification 
and characterization of peripheral blood monocytes. It has previously been shown that there 
are different monocyte populations, the classical (CD14 high) and the non-classical (CD14 
low). The non-classical population (about 10% of the total monocyte population) yields 
higher TNF levels after TLR stimulation (94, 95). The reduction of CD14 expression from 
smokers in unstimulated monocytes indicated an imbalance between classical monocytes. 
In this study, binding to CD14 or CD16 was not used in the selection of the monocytes, as 
such procedures may lead to cell activation (96, 97), and instead a method based on a nega-
tive selection was used. The monocytes can however also be activated by handling, isola-
tion and incubation with medium only (98, 99). 
TLR signaling in innate immune cells can be indirectly regulated by the SOCS (suppressors 
of cytokine signaling) family (100). SOCS 1, 2, and 3 are inhibitors of the TLR signaling, 
primarily by binding to molecules downstream of myD88-dependent NF-kB activation (101-
103). Cytokine expression induced by TLR is negatively correlated to SOCS-1 expression. 
It is believed that the lower the cytokine expression detected, the lower is the SOCS1 
expression, which is shown in alveolar macrophages in patients with COPD (104).
In the current study, where monocytes from smokers were stimulated by TLR ligands, the 
relative gene expressions for both SOCS-1 and pro-inflammatory mediators (including IL-6, 
TNF and CCL5) were higher in smokers compared to that observed in non-smokers.
This suggest that smoking induce a dysregulation downstream of the TLR activation in 
order to affect common mechanisms inducing the expression of both SOCS-1 and proin-
flammatory mediators. This may suggest that smoke exposure could also affect the SOCS-1 
mediated inhibition of NF-kB activation, making the inhibition less efficient. 
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Monocyte upregulation of pro-inflammatory mediators in smokers may provide clues for 
the increased pneumococci infection risk in this population. Human epithelial cells in the 
respiratory and nasopharynx tracts, as well as in other tissues, express surface proteins 
including platelet activating factor receptor (PAFr), polymertic immunoglobulin receptor 
(plgR), and plaelet endothelial cell adhesion molecule-1 (PECAM) (59, 61, 105), which 
act as host cell receptors for pneumococci, and thereby may enable ahesion and invasion. 
Pro-inflammatory cytokines, including TNF and IL-1, have been shown to upregulate the 
transcription of PAFR and plgR expression (24, 106, 107). In the present study, we have 
described an upregulation of pro-inflammatory mediators, including TNF, in smokers. This 
may lead to an increased receptor expression for adhesion and subsequent invasion of pneu-
mococci. 
We have shown here that CWPS from S. Pneumoniae is an effective activator of monocytes 
and NK cells, and that it induces transcription and secretion of pro-inflammatory mediators, 
similar to other TLR ligands investigated. Monocytes from smokers and non-smokers 
showed a different expression of inflammatory mediators and the cells from smokers 
exhibited a pronounced expression. Systemic innate immune response is affected by 
cigarette smoke, even in moderate, young smokers with normal lung function.
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FUTURE PERSPECTIVES
As shown in this thesis, capsular saccharides generate different immune responses. It 
would be of interest to investigate the immune response to all capsules included in the 
pneumococcal vaccine. This may be of importance for future vaccine development.
In addition, examination of CWPS impact for the respective capsule could be of interest. 
The upregulated immune response in smokers would be of interest to study further. Even 
though the results in the present work detected an imbalance in the system, the true impact 
of smoking and pneumococcal disease was not fully described. Investigating proposed 
pneumococci receptors on cell lines for the upregulation of adhesions molecules after 
cytokine or smoke exposure could better clarify the mechanisms.
Special population cohorts are risk groups for IPD. Among other groups 
immunocompromised patients are frequently represented. This population (e.g. lung 
transplanted patients) should be investigated according to immunologic responses.  
Also, what vaccine yields best protective results and also what are the immunological 
responses to vaccination in this cohort could be studied.
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CONCLUSIONS
•	 An ELISA was developed in order to evaluate the binding of S Pneumoniae to two 
previously suggested receptors. 
•	 An uncapsulated S Pneumoniae strain adhered to a greater extent to asialo-GM1 
than to lactotriaocylceramide receptors.
•	 The uncapsulated strain of S Pneumoniae adhered with high efficiency to asialo-
GM1, while two capsulated pneumococcal strains adhered with lower efficiency. 
This indicated that both capsulated and uncapsulated S Pneumoniae are capable of 
binding to asialo-GM1.
•	 The adhering ligand from S Pneumoniae responsible for the binding to asialo-
GM1 was purified and identified as cell wall polysaccharide (CWPS). 
•	 Phosphoryl choline residues in the pneumococcal CWPS are essential for the inter-
action between CWPS and the receptor asialo-GM1. 
•	 Among the three capsules investigated, capsule type 23 induced the strongest acti-
vation and cytokine release, followed by type 9 and type 3. 
•	 After stimulation with the different capsules, NK cells and NK-like T cells exhib-
ited the strongest activation, followed by monocytes.
•	 CWPS is an effective activator of immune cells that induces transcription and se-
cretion of pro-inflammatory mediators, similar to other TLR ligands investigated.
•	 After incubation with CWPS, monocytes from smokers exhibited an increased 
upregulation of pro-inflammatory mediators compared to non-smokers. 
•	 Non-smoker monocytes showed downregulation of immunoregulatory molecules 
IL-10 and SOCS-1, following CWPS stimulation, while this was not detected in 
cells from smokers.
•	 Immune response may directly upregulate the transcription of pneumococcal 
receptors expressed on the host cell surface, which could contribute to increased 
binding of pneumococci. 
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